Project Grant R00HL168433
Award Date 7/20/26
Completion Date 5/31/29
Dollars Obligated $249K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Honolulu, HI 96813, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Southern California $240,206 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 1, 2026, to engineer therapeutically programmed monocytes that adaptively immunomodulate the post-infarction myocardial microenvironment toward cardiac repair and regeneration. The award funds development of smart monocytes using synnotch receptor circuits that detect inflammation and respond by secreting...
- The National Heart Lung and Blood Institute awarded the Beckman Research Institute of the City of Hope $813,810 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on nucleotide supplementation as a treatment strategy for ischemic heart disease and myocardial infarction. The project investigates the role of nucleotide balance in cardiomyocyte proliferation and aims to apply these findings for cardiac repair using large animal models....
- The National Heart, Lung, and Blood Institute awarded the University of Arizona $562,733 on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop small molecule therapeutics for heart failure through reduction in tristetraprolin activity and improvement of cardiac metabolism. The project runs through May 31, 2027, with work performed in Tucson, Arizona. The research targets tristetraprolin, a zinc finger protein that regulates fatty acid uptake and oxidation...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services, awarded $1,619,582 to the University of Virginia on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the cardio-splenic axis in acute myocardial infarction and post-MI heart failure. The project examines the immunopathological mechanisms by which plasmacytoid dendritic cells orchestrate post-MI inflammation and cardiac dysfunction. The research team...
- The National Institutes of Health National Heart Lung and Blood Institute awarded $248,999 to The University of Iowa on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support fate-mapping of cardiac monocyte recruitment and specification. The award funds research investigating how diverse macrophage populations obtain their distinct transcriptional profiles following cardiac injury, with the goal of identifying spatiotemporal dynamics of macrophage recruitment...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $246,750 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate fibrotic signatures after regenerating and non-regenerating myocardial infarction. The funded research investigates cardiac fibrosis—the deposition of extracellular matrix components in the heart following myocardial injury. While early fibrosis can be protective after myocardial...
- The National Heart, Lung, and Blood Institute awarded Cedars-Sinai Medical Center $1.379 million on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cardioprotective mechanisms of Y RNA signaling in macrophages as a potential therapeutic approach to myocardial infarction. The research dissects how a small non-coding RNA called YREX3—secreted by therapeutically-enhanced cardiac stromal cells—signals macrophages to enhance their capacity for...
- The National Heart, Lung, and Blood Institute awarded University of Massachusetts Medical School $103,686 on December 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support basic research into translation control mechanisms in heart and lung disease. The funded research investigates how the RNase A family nuclease angiogenin stimulates blood vessel formation and why angiogenin dysfunction associates with heart failure, and separately examines how the bacterial...
- The National Heart, Lung, and Blood Institute awarded The Methodist Hospital Research Institute $755,573 on August 21, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the muscle-specific E3 ligase TRIM55 in autoimmune myocarditis pathogenesis. The research uses monogenic autoimmune myocarditis models based on TREX1 deficiency to examine how innate immune responses shape disease development. The work combines in vitro studies using human...
- The National Heart, Lung, and Blood Institute awarded The Washington University $550,896 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop targeted nanotherapy for acute myocardial infarction. The project, led by Principal Investigator Jianjun Guan, will encapsulate an engineered secretome derived from naive M0 macrophages into nanoparticles for intravenous administration to simultaneously address three critical post-infarction pathologies:...